NYXH Nyxoah

Nyxoah Announces Change to Board of Directors

Nyxoah Announces Change to Board of Directors

Nyxoah Announces Change to Board of Directors

Mont-Saint-Guibert, Belgium – October 24, 2022, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that Raymond Cohen resigned as member of the board of directors of the Company effective October 18, 2022.

About Nyxoah

Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Nyxoah completed two successful IPOs: on Euronext Brussels in September 2020 and NASDAQ in July 2021. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit .

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Contacts:

Nyxoah

Loic Moreau, Chief Financial Officer



0

Jeremy Feffer, VP IR and Corporate Communications



 

Attachment



EN
24/10/2022

Underlying

NYXHNyxoah

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Nyxoah

 PRESS RELEASE
Free
NYXH NYXOAH

Publication relating to transparency notifications

Publication relating to transparency notifications REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), February 27, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. Robert Taub / BMI Estate On February 26, 2026, Nyxoah received a transparency notification from Robert Taub and related person BMI Estate, following the passive crossing of a thr...

February 27, 2026 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Publication relative à des notifications de transparence

Publication relative à des notifications de transparence INFORMATION RÉGLEMENTÉE Publication relative à des notifications de transparence Mont-Saint-Guibert (Belgique), le 27 février 2026, 22:30h CET / 16:30h ET – Conformément à l'article 14 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels/Nasdaq : NYXH) annonce qu’elle a reçu une notification de transparence comme détaillée ci-dessous. Robert Taub / BMI Estate Le 26 février 2026, Nyxoah a reçu une notification de transparence de Robert Taub et d’une personne liée, BMI Estate, ...

February 27, 2026 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Information on the total number of voting rights and shares

Information on the total number of voting rights and shares REGULATED INFORMATION Information on the total number of voting rights and shares Mont-Saint-Guibert (Belgium), February 25, 2026, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares on February 20, 2026. Share capital: EUR 6,511,048.19 Total number of securities carrying voting rights: 43,662,403 (all ordinary shares) Total number of voting righ...

February 25, 2026 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Informations sur le nombre total de droits de vote et d'actions

Informations sur le nombre total de droits de vote et d'actions INFORMATION RÉGLEMENTÉE Informations sur le nombre total de droits de vote et d'actions Mont-Saint-Guibert (Belgique), le 25 février 2026, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 relative à la publicité des participations importantes, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publie les informations ci-dessous suite à l'émission de nouvelles actions le 20 février 2026. Capital : EUR 6.511.048,19 Nombre total de titres avec droits de vote : 43.662.403 (tous des actions ordinaires) Nom...

February 25, 2026 1 EN
 PRESS RELEASE
Free
NYXH NYXOAH

Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sh...

Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sheikh Shakhbout Medical City afin d'Améliorer la Prise en Charge du Traitement de l'AOS et d'Accélérer l'Accès à Genio au Moyen-Orient Nyxoah Annonce la Signature d'un Mémorandum d'Accord avec l'Hôpital Sheikh Shakhbout Medical City afin d'Améliorer la Prise en Charge du Traitement de l'AOS et d'Accélérer l'Accès à Genio au Moyen-Orient Mont-Saint-Guibert, Belgique – 18 février 2026, 22h05 CET / 16h05 ET – Nyxoah SA (Euronext Bruxelles/Nasdaq : NYXH) (« Nyxoah » ou la « Société ») une société de technologie médicale spéci...

February 18, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch